What is Aadi Bioscience?
Aadi Bioscience is dedicated to bringing transformational therapies to patients with specific genetic alterations in the mTOR pathway. The company's approach centers on developing precision medicines that can effectively target diseases driven by alterations in TSC1 or TSC2 genes, where conventional mTOR inhibitors may face challenges related to pharmacology, drug delivery, safety, or site-specific targeting. This focus positions Aadi Bioscience at the forefront of precision oncology, aiming to address unmet medical needs in a rapidly evolving field.
How much funding has Aadi Bioscience raised?
Aadi Bioscience has raised a total of $195.7M across 4 funding rounds:
Series A
$23M
Debt
$150K
Share Placement
$72.5M
Share Placement
$100M
Series A (2017): $23M with participation from Vivo Capital, Hermed Capital, Helsinn Investment Fund, Celgene Corporation, and Decheng Capital
Debt (2020): $150K led by PPP
Share Placement (2022): $72.5M, investors not publicly disclosed
Share Placement (2025): $100M, investors not publicly disclosed
Key Investors in Aadi Bioscience
Vivo Capital
Vivo Capital, founded in 1996, is a global healthcare investment firm with a focus on private and public equity, as well as venture capital, indicating a broad interest in life science innovation.
Hermed Capital
Hermed Capital, established in 2009, provides working capital finance to SMEs, demonstrating a capacity for flexible, privately funded solutions that support business growth.
Helsinn Investment Fund
The Helsinn Investment Fund, backed by the Helsinn Group, focuses on early-stage investment opportunities in areas of high unmet patient need, particularly in cancer therapeutics and diagnostics.
What's next for Aadi Bioscience?
The recent major strategic investment signifies a pivotal moment for Aadi Bioscience, likely enabling the company to accelerate its clinical development programs, expand its research and development capabilities, and potentially scale its operations. This enterprise-level backing suggests strong confidence from investors in Aadi's therapeutic approach and its potential to achieve significant clinical and commercial milestones. The company is poised to leverage this financing to further its mission of delivering novel treatments to cancer patients with specific genetic profiles.
See full Aadi Bioscience company page
